Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of PX-866 and Docetaxel in Patients With Solid Tumors

NCT01204099 is registered in ClinicalTrials.gov with Cascadian Therapeutics Inc. as lead sponsor.

NCT NCT01204099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01204099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of PX-866 and Docetaxel in Patients With Solid Tumors
Lead sponsor
Cascadian Therapeutics Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2010
Completion date
February 28, 2014
Enrollment
223 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer (nsclc), squamous cell carcinoma of the head and neck (scchn)